New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
Go back to New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years| Asianada, Inc. (NASDAQ: ASND) | Delayed: 228.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.00 | 52 Week High | $21.79 | |||
| Open | $228.00 | 52 Week Low | $11.92 | |||
| Day High | $228.00 | P/E | N/A | |||
| Day Low | $228.00 | EPS | $-0.07 | |||
| Volume | 286 | |||||
